Sarcoma UK is delighted to announce a new partnership, we3can, to fund research into the three most common childhood cancers.
This exciting collaboration, which is made up of Brain Tumour Research, Leukaemia UK, and Sarcoma UK, is driven by an essential mission – to make real progress in the treatment and cure of childhood cancer.
As we3can, we are dedicated to funding pioneering research into the prevention, treatment and cure of the most common childhood cancers: brain tumours, leukaemia, and sarcomas. Together, these three cancers make up 78% of all cancers in children.
We are inviting companies, individuals, and organisations to support this vital work, and plans to raise funds through donations, events, and sponsorship, including opportunities to partner with the collaboration.
Announcing the collaboration, Dan Knowles, Chief Executive of Brain Tumour Research, Fiona Hazell, Chief Executive of Leukaemia UK, and Richard Davidson, Chief Executive of Sarcoma UK, said: “We are delighted to announce the we3can collaboration and are committed to funding vital research to help families affected by brain tumours, leukaemia and sarcomas.
‘Together these three cancers make up 78% of all cancers in kids. We look forward to working with partners to accelerate world-class research into kinder, less toxic treatments for these cancers. By working together, we can help save lives and ensure that more kids with cancer can have a carefree childhood and a future.‘
Visit we3can for more information about the collaboration’s commitment to find better and kinder treatments, and ultimately a cure for childhood cancers.
